April 24, 2024

The Orodispersible Tablets Market is driven by Increasing Demand for Convenient Drug Delivery

The orodispersible tablets market has witnessed significant growth in recent years owing to the increasing demand for convenient drug delivery formats, especially among geriatric and pediatric population segments who face difficulty in swallowing conventional tablets and capsules. Orodispersible tablets disintegrate and dissolve rapidly in the saliva, thereby eliminating the need for water during administration. This makes them a preferred format for drugs meant for neurological disorders, cough & cold, allergies, and other therapeutic areas. The tablets also enable improved bioavailability as the drug gets absorbed directly into the systemic circulation from the oral cavity. Furthermore, the technology allows for taste masking and production of orally disintegrating formulations containing bitter drugs.

The global Orodispersible Tablets Market is estimated to be valued at US$ 4.9 Bn in 2023 and is expected to exhibit a CAGR of 8.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Some of the key trends in the orodispersible tablets market include:

– Technology advancements: Manufacturers are focusing on developing newer technologies such as freeze-drying and spray-drying to improve the taste and speed of disintegration of orodispersible tablets. 3D printing is also emerging as an innovative technology for manufacturing customized orodispersible tablets.

– Pediatric formulations: There is a growing demand for orodispersible tablet formulations of pediatric drugs due to ease of swallowing. Leading companies are launching new orodispersible tablet products targeting the pediatric population.

– Focus on CNS drugs: Many pipeline drugs for central nervous system disorders are being developed in the form of orodispersible tablets as these conditions often require emergency treatment. This will boost market growth over the forecast period.

– Regional expansion strategies: Key players are expanding their geographic footprint through partnerships and acquisitions to tap the potential of emerging markets and strengthen their global presence in the orodispersible tablets industry.
Porter’s Analysis

Threat of new entrants: The threat of new entrants in the global Orodispersible Tablets market is low as it requires high capital requirement for R&D and product approval from regulatory authorities.

Bargaining power of buyers: The bargaining power of buyers in the global Orodispersible Tablets market is high due to the presence of generic drugs and availability of substitutes.

Bargaining power of suppliers: The bargaining power of suppliers in the global Orodispersible Tablets market is moderate as some key raw materials have limited sources of production.

Threat of new substitutes: The threat of new substitutes in the global Orodispersible Tablets market is high due to the availability of other drug delivery formats.

Competitive rivalry: The competitive rivalry in the global Orodispersible Tablets market is high due to the presence of many branded as well as generic players.

Key Takeaways

The global Orodispersible Tablets market is expected to witness high growth during the forecast period of 2023 to 2030. The market size for Orodispersible Tablets was valued at 4.9 Bn in 2024 and is expected to grow at a CAGR of 8.1% during the forecast period.

Regional analysis: North America is expected to dominate the global Orodispersible Tablets market during the forecast period owing to high adoption of advanced drug delivery formats and increasing prevalence of geriatric population. Asia Pacific is expected to grow at the fastest pace during the forecast period owing to presence of major generic drug producing countries and increasing healthcare spending.

Key players: Key players operating in the Orodispersible Tablets market are Alnylam Pharmaceuticals, IntelGenx, Pfizer, Solvay, BioAlliance Pharma and others. Alnylam Pharmaceuticals specializes in producing orodispersible formulations for various therapeutic applications. IntelGenx utilizes its proprietary drug delivery technology VersaFilm for producing orodispersible films.

*Note:

  1. Source: Coherent Market Insights, Public sources, Desk research
  2. We have leveraged AI tools to mine information and compile it